29 results about "Superior vena cava" patented technology

A method is provided that includes inserting an inflow cannula of a left ventricular assist device (LVAD) of a LVAD system into a left chamber of a heart of a patient transeptally via a right atrium and a superior vena cava (SVC). An outflow cannula of the LVAD is coupled to a left subclavian artery or a left axillary artery. Other embodiments are also described.

A method may involve creating a first opening in a right pulmonary artery and a second opening in a superior vena cava. A shunt may be percutaneously delivered into the first opening and the second opening. A stent may be percutaneously delivered into the superior vena cava adjacent to the shunt. The stent can comprise a covering to at least partially prevent flow of blood from the shunt through the stent and / or may be at least partially flexible to allow the stent to bend away from walls of the superior vena cava in response to inflow of blood through the shunt. The stent may be sized to seal against the superior vena cava at a first end and a second end of the stent to trap blood between the stent and the walls of the superior vena cava.

Apparatus and methods for repairing a cardiac valve, e.g., a tricuspid valve, are provided. The apparatus may include a prosthetic device coupled to an elongated support coupled to a stent configured to be implanted within a vessel, e.g., the superior vena cava, to suspend and maintain the prosthetic device within the cardiac valve. The support may include a proximal, delivery portion detachably coupled, in a delivery state, to a distal, implantable portion coupled to the prosthetic device. The prosthetic device may be formed of biocompatible material coupled to a frame, and may have prosthetic leaflets that allows blood to flow therethrough in one direction during diastole, but prevents blood regurgitation during systole. The stent further may include features configured to resist migration of the stent within the vessel, as well as to prevent in-folding of the stent during deployment.

The utility model relates to a multifunctional catheter for superior vena cava triggering focus mapping and phrenic nerve pace-making, which comprises a catheter body and a spiral electrode tip arranged at the far end of the catheter body, and a plurality of pace-making electrode groups are arranged on the spiral electrode tip. The catheter body and the spiral electrode tip are telescopically arranged in the sheath and can extend out of the open end of the sheath; the spiral electrode tip is in a contraction configuration in the sheath, and can be converted to an expansion configuration when extending out of the sheath and extending into a phrenic nerve pace-making area in the superior vena cava; the starting end of the spiral electrode tip is connected with a center mapping catheter coaxial with the catheter body, and a plurality of mapping electrode sets are arranged on the center mapping catheter. Compared with the prior art, the multifunctional catheter has the advantages that the spiral electrode tip can be stably attached to the inner wall of the superior vena cava, and the multifunctional catheter can be matched with a central mapping catheter to map a superior vena cava trigger range while playing a pace-making role.

Systems and methods are provided for treating conditions such as heart failure and / or pulmonary hypertension by at least partially occluding flow through the superior vena cava for an interval spanning multiple cardiac cycles. A catheter with an occlusion device is provided along with a controller that actuates a drive mechanism to provide at least partial occlusion of the patient's superior vena cava, which reduces cardiac filling pressures, and induces a favorable shift in the patient's Frank-Starling curve towards healthy heart functionality and improved cardiac performance. The system may include sensors to determine the degree of occlusion of the superior vena cava. The occlusion system may be used to reduce volume in a heart and facilitate a cardiac procedure. The occlusion system may be used to relieve an overloaded chamber during and / or after deploying a VAD.

Systems and methods are provided for treating conditions such as heart failure and / or pulmonary hypertension by at least partially occluding flow through the superior vena cava for an interval spanning multiple cardiac cycles. A catheter with an occlusion device is provided along with a controller that actuates a drive mechanism to provide at least partial occlusion of the patient's superior vena cava, which reduces cardiac filling pressures, and induces a favorable shift in the patient's Frank-Starling curve towards healthy heart functionality and improved cardiac performance. The system may include sensors to determine the degree of occlusion of the superior vena cava. The occlusion system may be used to reduce volume in a heart and facilitate a cardiac procedure. The occlusion system may be used to relieve an overloaded chamber during and / or after deploying a VAD.

The utility model belongs to the field of medical catheter instruments, and particularly relates to a dialysis catheter. Comprising a catheter extending in the longitudinal direction, the catheter comprises a catheter body at the far end and at least two auxiliary catheters communicated with the near end of the catheter body, inner cavities correspondingly communicated with the auxiliary catheters are formed in the catheter body, and side holes corresponding to the far ends of the inner cavities are formed in the catheter body; the base is connected to the near end of the auxiliary catheter and is communicated with the connected auxiliary catheter. The whole dialysis catheter is buried subcutaneously, the wound of the puncture medical instrument to the skin is small and easy to recover, the infection risk is greatly reduced, the base is not exposed out of the body and is relatively stably connected with the skin, the risk that the base is accidentally dragged out does not exist, and the influence on the life of a patient is also remarkably reduced. In addition, sterile liquid can be injected into the dialysis catheter through the side hole, so that the catheter cannot be tightly attached to the superior vena cava, the probability of thrombus formation is reduced, and the dialysis catheter has the advantages of being not prone to infection, small in influence on life and friendly to patients.

Transvascular diaphragm pacing systems (TDPS) and methods are disclosed for providing respiratory therapy to a patient. The TDPS can provide rapid insertion and deployment of endovascular pacing electrodes in critically ill patients who require intubation and invasive PPMV in order to support the physiological requirements of the human ventilatory system. The systems and methods make best use of the contractile properties of the diaphragm muscle and prevent muscle disuse and muscle atrophy. This can be carried out by engaging the phrenic nerves using patterned functional electrical stimulation applied to endovascular electrodes that are temporarily and reversibly inserted in central veins of the patient, such as the left subclavian vein and the superior vena cava. The TDPS can be designed to seamlessly interface with any commercially available positive-pressure ventilatory assistance / support equipment such as is commonly in use in hospital intensive care units (ICU) for treating critically ill patients with breathing insufficiencies, pain, trauma, sepsis or neurological diseases or deficits.

Systems and methods and devices are provided for treating conditions such as heart failure and / or pulmonary hypertension by at least partially occluding flow through the superior vena cava for an interval spanning multiple cardiac cycles. A catheter with an occlusion device is provided along with a controller that actuates a drive mechanism to provide at least partial occlusion of the patient's superior vena cava, which reduces cardiac filling pressures, and induces a favorable shift in the patient's Frank-Starling curve towards healthy heart functionality and improved cardiac performance. The occlusion device may include a lumen obstructed by a relief valve that may permit fluid flow through the occlusion device to release an excessive build-up of pressure.

The present invention relates to an access and occluder device, in particular a heart valve regurgitation drum and optional occlusion disc and / or annular stent for managing and providing a level of intentional regurgitation in a transcatheter heart valve replacement, in particular an orthogonally delivered transcatheter prosthetic heart valve having a first inner flow control component / valve, a first inner regurgitation control component and an outer annular support frame having compressible wire cells.SOLUTION: The compressible wire cells facilitate folding flat along the z-axis and compressing the valves vertically along the y-axis or orthogonal to the central axes of the flow control components, enabling the delivery and placement of very large diameter valves from the inferior or superior vena cavae to the tricuspid valves or transatrially to the mitral valves, having heights of about 5 to 60mm and diameters of about 25 to 80mm, without the need for an oversized catheter and without the need for delivery and placement from a catheter with a sharp approach angle.SELECTED DRAWING: Figure 3

In some embodiments, a method includes a shaft having a side catheter guide attached thereto via a guide coupler into an inferior vena cava and a superior vena cava such that the guide coupler is disposed in a right atrium, and applying a distal force to a proximal portion of the side catheter guide such that a distal end of the side catheter guide deflects laterally about the guide coupler towards a septum. The method further includes extending a side catheter that is disposed within the side catheter guide distally from the side catheter guide towards and into contact with the septum. The method further includes, with the side catheter in contact with the septum, extending a septum penetrator that is slidably disposed within the side catheter distally from the side catheter such that the septum penetrator pierces the septum.

The present disclosure provides a transcatheter occluder device (1) for high venosum atrial septal defects (hv-asds). The device (1) comprises at least one connecting wire (2), a left occluder disk (3), and an asymmetrically designed right occluder disk (4). A first occluder form (A) includes a rear fixation lobe (5), an upper fixation lobe (6), and a lower fixation lobe (7), with the connecting wire (2) connected to the left occluder disk (3) and formed to provide a crown shape. A second occluder form (B) includes a first ring stabilizer (8) as a spiral ring and a second stabilizer (9) at the end of the connecting wire (2) for insertion into the superior vena cava and the inferior vena cava. The connecting wire (2) comprises a mesh wire. The device's (1) asymmetrical design allows secure anchoring to the inferior vena cava rim, addressing the unique challenges of high venosum atrial septal defects.

Described herein are shunt devices configured to achieve a targeted reduction in peak systolic pressure by percutaneously shunting from the superior vena cava to the right pulmonary artery. The shunt devices include a check valve with a cracking pressure to preserve a minimal transpulmonary pressure. Also described herein are flow diversion devices placed between pulmonary circulation vessels and venous vessels. The disclosed flow diversion devices are physiologically responsive through an adjustable orifice that can be adjusted after initial implantation through a non-invasive or minimally invasive procedure. Disclosed herein are flow control systems that are configured to reduce recruitment of blood from the splanchnic system. The flow control systems include a variable orifice constrictor (e.g., a covered stent) and a controller that delivers energy to the constrictor to reduce the cross-sectional area of the lumen through the variable orifice constrictor.

A method of treating heart failure in a patient includes delivering an occlusion device through the vasculature into the Superior Vena Cava ("SVC") of the patient. The occlusion device is activated within the SVC such that blood flow from the SVC is effectively continuously occluded for a period of about 6 hours. After the 6-hour period of time, the occlusion device within the SVC is deactivated. The occlusion device is removed from the vasculature of the patient.

The utility model relates to the technical field of medical teaching, and discloses a human body model used for anesthesia ultrasonic teaching, which comprises a simulated human body, a chest simulation module, a bionic pump, a liquid storage device and an arm simulation module, and is characterized in that the chest simulation module comprises a simulated heart, a simulated head and arm trunk and a simulated superior vena cava; the left atrium of the simulated heart is communicated with the output end of the bionic pump, the right ventricle of the simulated heart and the input end of the bionic pump are communicated with the liquid storage device, the arm simulation module comprises a first pipeline and a second pipeline, and the left ventricle of the simulated heart is communicated with the front end of the first pipeline and the front end of the second pipeline through a simulated head-arm shaft. And the rear end of the first pipeline and the rear end of the second pipeline are respectively communicated with the right atrium of the simulated heart through the simulated superior vena cava. A plurality of simulation modules are arranged in the simulation human body, the comprehensiveness is high, the blood circulation of the human body can be simulated, and the simulation degree is high.

A method for providing therapeutic treatment to reduce pre-load may be provided. The method may include placing a ventricular assist device (VAD) at least partially within a left ventricle or a right ventricle of a patient, and placing a catheter-based device including an adjustable flow limiting element (FRE) such that the FRE is disposed within a superior vena cava (SVC) of the patient. The method may include receiving information from the VAD and / or conduit-based FRE device, determining a first determination value based on the information, and controlling at least one performance parameter of the VAD and / or conduit-based device based on the first determination value.

A single vena cava crossing tricuspid valve device comprises at least one stent structure; a first end configured for implantation in the inferior vena cava (IVC) and anchoring the device in the IVC, optionally at least partially covered; a second end configured for implantation in the superior vena cava (SVC) and anchoring the device in the SVC, optionally at least partially covered; a first valve connected to at least a portion of the first end so that when the CCTD is implanted, it is located in at least a portion of the right atrium (RA) above the IVC; a second valve connected to at least a portion of the second end so that it is located in at least a portion of the right atrium (RA) below the SVC or at least partially within the SVC, below the azygos vein; and sealing means.

This invention discloses a dilator for three-dimensional atrial septal puncture, comprising a tube body including a central chamber, a distal end, and a proximal end. The distal end of the tube body has a curved structure, and a cutting end is provided at the distal end of the curved structure. The dilator of this invention allows the position of the needle tip to be accurately displayed in real time in a three-dimensional system, and eliminates the risk of needle tip damage to the superior vena cava and endocardial tissue in other three-dimensional puncture methods.

The invention discloses an integrated optical fiber sensor tracheal catheter structure and a blood flow monitoring system.The integrated optical fiber sensor tracheal catheter structure comprises a catheter body, a plurality of sets of optical fiber sensor assemblies are embedded in the catheter body, the optical fiber sensor assemblies are packaged and fixed in the catheter body through biocompatible materials, and the surfaces of the optical fiber sensor assemblies are smooth and free of sharp protrusions; the optical fiber sensor assembly is used for sensing mechanical vibration or pressure change caused by blood flow of a target blood vessel adjacent to the thoracic cavity after the catheter is placed into the trachea. The defect that in the prior art, a great blood vessel blood flow monitoring means in the thoracic cavity is high in invasiveness or continuous monitoring cannot be achieved is overcome. Various types of optical fiber sensors are integrated in the tracheal catheter, continuous and real-time monitoring of blood flow of blood vessels such as aorta, superior vena cava and pulmonary artery of a patient is achieved, clinical monitoring efficiency and patient safety are improved, meanwhile, the tracheal catheter can be conveniently fixed, and the situation that the monitoring result is inaccurate due to catheter displacement is avoided.

The invention discloses an ultrasound-guided central vein minimally invasive catheterization method and device for breast cancer chemotherapy. The method comprises the following steps: acquiring affected side operation and radiotherapy data before catheterization to construct an individualized anatomical risk model; performing three-dimensional scanning on the puncture area, collecting multi-mode blood vessel microenvironment characteristics, generating a fusion image, and identifying a lymphatic vein high-risk area; determining an optimal puncture path through a safety scoring algorithm; in-plane puncture is guided by ultrasound, bio-impedance and blood flow spectrum are monitored synchronously, and automatic early warning is performed when abnormity occurs; the catheter is fed in normally, pressure, position offset and intracavitary electrocardio characteristics are fed back in real time through a microsensor at the far end of the guide wire, and the pushing depth of the catheter is dynamically corrected till the tip end is located on the head side of the junction of the superior vena cava and the right atrium. According to the method, the technical problems of inaccurate catheterization positioning, high complication risk and dependence on radiation caused by anatomical structure variation and complex blood vessel conditions of a breast cancer patient in an ultrasonic guided catheterization method in the prior art are solved.

The utility model provides an internal jugular vein compressor, and belongs to the technical field of medical instruments. The internal jugular vein compressor comprises an upper clamping plate and a lower clamping plate which are installed on an operating bed, two fixing blocks are symmetrically and fixedly connected to the two sides of the outer wall of one end of the upper clamping plate, sliding grooves are formed in the outer walls of the tops of the fixing blocks, a plurality of first limiting clamping grooves are formed in the inner walls of the sliding grooves, and a connecting plate is fixedly connected to one end of the lower clamping plate; the lower clamping plate is fixedly connected with three inner clamping plates which are linearly arranged and distributed; the compression assembly is used for compressing the neck veins of the patient. According to the technical scheme, the compression assembly is arranged to compress the neck vein of a patient, so that the neck vein, close to the superior vena cava, of the patient is not highlighted any more, a PICC catheter is prevented from entering the internal jugular vein in an ectopic mode, and meanwhile adjustment can be conducted according to the neck size of the patient so as to adapt to different patients.

A method may be provided for providing a therapeutic measure to reduce preload. The method may include placing a ventricular assist device (VAD) at least partially inside either the patient's left or right ventricle, and placing a catheter-based device including an adjustable flow-limiting element (PRE) such that the PRE is placed inside the patient's superior vena cava (SVC). The method may include receiving information from the VAD and / or catheter-based PRE device, determining a first determination value based on the information, and controlling at least one performance parameter of the VAD and / or catheter-based device based on the first determination value.

Systems and methods are provided for treating conditions such as heart failure and / or pulmonary hypertension by at least partially occluding flow through the superior vena cava for a duration spanning multiple cardiac cycles. Catheters with occlusion devices are provided, as well as controllers that actuate a drive mechanism to provide at least partial occlusion of a patient's superior vena cava, which reduces cardiac filling pressures and induces a favorable shift in the patient's Frank-Starling curve toward healthy cardiac functionality and improved cardiac performance. The system can include sensors to determine the degree of occlusion of the superior vena cava. The occlusion system can be used to reduce cardiac volume and facilitate cardiac surgery. The occlusion system can be used to relieve overburdened chambers during and / or after deployment of a VAD.

In some embodiments, a method includes a shaft having a side catheter guide attached thereto via a guide coupler into an inferior vena cava and a superior vena cava such that the guide coupler is disposed in a right atrium, and applying a distal force to a proximal portion of the side catheter guide such that a distal end of the side catheter guide deflects laterally about the guide coupler towards a septum. The method further includes extending a side catheter that is disposed within the side catheter guide distally from the side catheter guide towards and into contact with the septum. The method further includes, with the side catheter in contact with the septum, extending a septum penetrator that is slidably disposed within the side catheter distally from the side catheter such that the septum penetrator pierces the septum.

A method of treating heart failure in a patient includes delivering an occlusion device through the vasculature into the Superior Vena Cava (“SVC”) of the patient. The occlusion device is activated within the SVC such that blood flow from the SVC is effectively continuously occluded for a period of about 6 hours. After the 6-hour period of time, the occlusion device within the SVC is deactivated. The occlusion device is removed from the vasculature of the patient.

The prosthetic heart valve may be delivered to a target native heart valve site via one or more delivery catheters. In some embodiments, a prosthetic heart valve is implanted using a catheter-based deployment system that includes a plurality of control lines. In particular embodiments, the deployment system may include a retrieval catheter that may be used to recapture the prosthetic heart valve back into the delivery sheath after the prosthetic heart valve is extruded from the delivery sheath. The prosthetic heart valve occupies a small delivery profile, facilitating a smaller delivery catheter system to advance to the heart. Some delivery catheter systems may include curved control catheters and / or deflectable catheters to facilitate deployment of the prosthetic heart valve to the native tricuspid valve site via either the superior vena cava or the inferior vena cava.

The invention specifically discloses a clinical evaluation method and equipment for the performance of a hemodialysis catheter, a medium and a program product. The method comprises the following steps: carrying out geometric modeling on the hemodialysis catheter and a superior vena cava; performing high-precision grid division and blood flow analog simulation on the geometric models of the hemodialysis catheter and the superior vena cava; boundary condition setting is conducted on all boundaries of a fluid domain in the geometric model, and eddy current analysis and flow weight construction are conducted; through particle tracking in the hemodialysis catheter, integration is carried out on the backflow particle proportion in a volume integration mode in the blood flow area around the whole catheter, and recirculation rate calculation is carried out. According to the method, the estimation accuracy of the recirculation rate of the hemodialysis catheter can be improved, and theoretical guidance for performance optimization of the hemodialysis catheter is met.